ozanimod

3 Potential New Drugs Held Up by the Shutdown
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
Flag link:
The 20 Hottest Pipeline Drugs to Watch in 2019
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Celgene to launch five new products through to 2020
Celgene to launch five new products through to 2020
PM Live
Celgene
Revlimid
FDA
fedratinib
ozanimod
luspatercept
bb2121
liso-cel
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
CP Wire
Celgene
ozanimod
multiple sclerosis
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene
ozanimod
multiple sclerosis
Flag link:
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Medical Marketing and Media
Celgene
Novartis
ozanimod
Gilenya
MS
multiple sclerosis
patents
Flag link:
Pharma's 2 Biggest Setbacks in 2018
Pharma's 2 Biggest Setbacks in 2018
Motley Fool
AbbVie
Celgene
Rova-T
ozanimod
Flag link:
Celgene executive blames Receptos for ozanimod filing fail
Celgene executive blames Receptos for ozanimod filing fail
Fierce Biotech
Celgene
Receptos
ozanimod
Flag link:
Celgene's timeline for refiling ozanimod gets mixed reviews
Celgene's timeline for refiling ozanimod gets mixed reviews
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
FDA
Flag link:
A metabolite will make or break Celgene's ozanimod
A metabolite will make or break Celgene's ozanimod
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
metabolite
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
CP Wire
Celgene
ozanimod
relapsing multiple sclerosis
MS
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene Corporation
multiple sclerosis
ozanimod
Flag link:
Arena Pharmaceuticals Takes Aim at Celgene
Arena Pharmaceuticals Takes Aim at Celgene
Motley Fool
Arena Pharmaceuticals
Celgene
etrasimod
ozanimod
ulcerative colitis
Flag link:
How Bad Is Celgene's FDA Foul-Up? Two Decades Of Biotech History Says It Can't Be Good
How Bad Is Celgene's FDA Foul-Up? Two Decades Of Biotech History Says It Can't Be Good
Forbes
Celgene
biotech
FDA
RTF letters
ozanimod
Flag link:
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Stat
Celgene
FDA
MS
multiple sclerosis
ozanimod
Flag link:
Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter
Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter
Motley Fool
Celgene
etrasimod
ozanimod
Arena Pharmaceuticals
MS
multiple sclerois
Flag link:
3 Big Biotech Stocks With Major Catalysts on the Way
3 Big Biotech Stocks With Major Catalysts on the Way
Motley Fool
biotech
AbbVie
Neurocrine Biosciences
Elagolix
Celgene
ozanimod
Gilead Sciences
bictegravir
Flag link:
5 Biggest New Drugs of 2018
5 Biggest New Drugs of 2018
Motley Fool
Gilead Sciences
Bictegravir/F/TAF
Novo Nordisk
semaglutide
Ozempic
Incyte
epacadostat
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
Flag link:

Pages